Biocon Chair Mazumdar-Shaw Says Insulin Expansion to Make Firm Top Hub in Five Years
2026-06-16 02:43:35
Biocon Executive Chairperson Kiran Mazumdar-Shaw said she is confident the company’s investment and capacity expansion in insulin will make it the top hub for the drug in the next five years. In an exclusive conversation, according to Bloomberg, she spoke with Haslinda Amin.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
